Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Iovance Biotherapeutics Inc (IOVA) USD0.000041666

Sell:$22.00 Buy:$23.00 Change: $0.42 (1.86%)
NASDAQ:0.04%
Market closed |  Prices as at close on 14 November 2019 | Switch to live prices |
Sell:$22.00
Buy:$23.00
Change: $0.42 (1.86%)
Market closed |  Prices as at close on 14 November 2019 | Switch to live prices |
Sell:$22.00
Buy:$23.00
Change: $0.42 (1.86%)
Market closed |  Prices as at close on 14 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.

Contact details

Address:
999 Skyway Rd Ste 150
SAN CARLOS
94070-2724
United States
Telephone:
+1 (650) 2607120
Website:
www.iovance.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IOVA
ISIN:
US4622601007
Market cap:
$2.85 billion
Shares in issue:
126.19 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Iain Dukes
    Chairman of the Board
  • Maria Fardis
    President, Chief Executive Officer and Director
  • Timothy Morris
    Chief Financial Officer and Corporate Secretary
  • Frederick Vogt
    General Counsel
  • Friedrich Graf Finckenstein
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.